Pharmafile Logo

Breaking Down the Barriers to Effective Treatment of Hepatitis C in Latin America

August 25, 2015 | HCV, Latin America, hepatitis C 

Published in eyeforpharma June 9 by Rachel Howard and Raquel Nunez.

If left untreated, hepatitis C leads to chronic health problems putting a huge strain on national healthcare resources.

During the course of my working life, hepatitis C is one of the therapy areas in which I have seen the most dramatic advances in terms of treatment.  It is definitely one of pharma’s success stories. It has experienced rapid evolution from interferon- and ribavirin-based treatment in 1998, through pegylated interferon-based regimens and protease inhibitors and on to the recent wave of direct-acting antiviral therapies available today. It would not be an exaggeration to say that these interferon-free treatment regimens, with high efficacy (Sustained Virological Response (SVR) rates approaching 100%), minimal side effects and short treatment durations, have the potential to revolutionize the treatment of hepatitis C.

This article considers a more complex reality; how the availability of such exciting new treatments does not necessarily result in a treatment “revolution” in many emerging markets. Specifically, I will explore this in the context of the interesting example of Latin America. 

Read the full article http://www.researchpartnership.com/news/2015/06/breaking-down-the-barriers-to-effective-treatment-of…

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Guide

UX research

Article: Why pharma must trust the science of behaviour

In a recent interview with PME Magazine, Dan Coffin, Director explains why the application of behavioural science will be key to better health far beyond COVID-19.Read the full article here:...

Case study

Using qualitative conjoint to assess willingness-to-pay

Consumer health specialist joins Research Partnership Inc

Global healthcare market research consultancy Research Partnership has appointed Jennifer Stewart as a Director in their US offices in Philadelphia.

Article: What’s next? How behavioural science can support pharma’s future

Dan Coffin, Director explains why now is an opportune time for pharma marketers to embrace behavioural science. Read his latest article for PME Magazine.https://bit.ly/31ef6rh

Video: UX/ Experience design research

Director and UX expert Liza Pliss discusses Research Partnership's approach to user experience research and shares an example of a project where using design thinking led to an agile approach...

White paper: The impact of COVID-19 on chronic disease management

Therapy Watch, Research Partnership's syndicated PRF tracker, has been investigating the impact of COVID-19 on chronic disease management. In this white paper, Research Partnership share some of the insights and...

Article: Pricing a coronavirus vaccine

Using findings from Research Partnership's recent COVID-19 impact study, Market Access Directors Rachel Howard and Brett Gardiner and Consultant Suzan Serip explore the challenges of pricing a coronavirus vaccine. Read...

News: Living with Ulcerative Colitis and Crohn’s Disease

Living with Ulcerative Colitis (UC) and Crohn’s Disease (CD) are new patient syndicated reports which offer valuable insights into patient attitudes and behaviour towards their condition, treatments and unmet needs. These reports...

Interactive infographic

Living With: The journey from the patient’s perspective